Algamdi Bader N, ALdahlan Hussam W, ALALhareth Hussain, Alghamdi Radhwan, Alkhouzaie Moath T, ALahmari Nawaf, Alhudaifi Abdulrahman, Alkasih Yaser, Elyahia Wyle, ALghamdi Khalid
Dermatology, King Fahd Hospital of the University, Khobar, SAU.
Vascular surgery, King Fahad University Hospital, Khobar, SAU.
Cureus. 2020 Dec 17;12(12):e12126. doi: 10.7759/cureus.12126.
Background Isotretinoin is the most effective treatment for moderate to severe acne. However, isotretinoin has many side effects related to its use. Since 1983, when Hetzen reported the first occurrence of new depressive symptoms in patients treated with isotretinoin, a lot of controversies emerged regarding the causal relationship between isotretinoin and depression. Objective To evaluate depression among acne patients treated with isotretinoin versus doxycycline at King Fahad Hospital of the University between December 2019-March 2020. Methods Using the Global Acne Grading System, patients aged 18 - 30 years old with moderate to severe acne vulgaris who have not received isotretinoin previously and has no personal or family history of any psychiatric illnesses, were evaluated for depression using the patient health questionnaire-9 before starting treatment and 8 weeks after. Twenty-nine patients had met the inclusion criteria and were included in the study. Results Of the 29 patients included, 18 patients completed the study (nine males, nine females). Twelve patients received isotretinoin 0.5mg/kg (study group) and six patients received doxycycline 100mg (control group). The mean depression score for the isotretinoin group has decreased from (4 ± 2.48) to (3.08 ± 2.84) but the result was statistically insignificant with a p-value of 0.19, CI (-5.28, 2.36). For the doxycycline group, the mean depression score has decreased from (5.5 ± 2.5) to (2.83 ± 0.75) with a p-value of 0.043, CI (0.12, 5.21). There was no statistically significant difference in the mean depression score between the two groups after 8 weeks of starting treatment [p-valve 0.837, CI (-2.28, 2.78)]. Conclusion This study showed that, after 8 weeks of starting treatment, isotretinoin at 0.5 mg/kg has no risk of developing depression. The results of this study did not reveal a direct relationship between the use of isotretinoin and the development of depression. Furthermore, optimum control and treatment of acne vulgaris have shown to improve depression scores.
背景 异维A酸是治疗中度至重度痤疮最有效的药物。然而,异维A酸有许多与其使用相关的副作用。自1983年赫岑首次报告使用异维A酸治疗的患者出现新的抑郁症状以来,关于异维A酸与抑郁症之间的因果关系出现了许多争议。目的 评估2019年12月至2020年3月在法赫德国王大学医院接受异维A酸与多西环素治疗的痤疮患者中的抑郁情况。方法 使用全球痤疮分级系统,对年龄在18至30岁、患有中度至重度寻常痤疮、此前未接受过异维A酸治疗且无任何精神疾病个人或家族史的患者,在开始治疗前和治疗8周后使用患者健康问卷-9评估抑郁情况。29名患者符合纳入标准并被纳入研究。结果 在纳入的29名患者中,18名患者完成了研究(9名男性,9名女性)。12名患者接受异维A酸0.5mg/kg(研究组),6名患者接受多西环素100mg(对照组)。异维A酸组的平均抑郁评分从(4±2.48)降至(3.08±2.84),但结果无统计学意义,p值为0.19,置信区间为(-5.28,2.36)。对于多西环素组,平均抑郁评分从(5.5±2.5)降至(2.83±0.75),p值为0.043,置信区间为(0.12,5.21)。开始治疗8周后,两组的平均抑郁评分无统计学显著差异[p值0.837,置信区间为(-2.28,2.78)]。结论 本研究表明,开始治疗8周后,0.5mg/kg的异维A酸无导致抑郁的风险。本研究结果未揭示异维A酸的使用与抑郁症发生之间的直接关系。此外,寻常痤疮的最佳控制和治疗已显示可改善抑郁评分。